
Aspivix raises 1.95 million euros via crowdfunding campaign

Share this article
Aspivix, the Swiss start-up behind Carevix™, an innovative device designed to transform gynecological practices, recently launched a crowdfunding campaign that has already raised 1.9 million euros. The initiative aims to bring together a community committed to supporting a technology focused on women’s comfort and health.
With 85 investors, the crowdfunding campaign, accessible on the Capital Cell platform, is open to all those wishing to support this major advance in women’s health. In just a few days, the campaign reached a funding level of € 1.95 million. The target is € 2.150.000. The fundraising will continue until 15 March 2025, with the aim of further industrializing the device and extending its commercialization to other markets.
A revolution inspired by a concrete problem
The Aspivix adventure began with a question posed between brothers: Julien Finci, an engineer, regularly asked David, a gynecologist, about aspects of his profession that could be improved. This is how the issue of Pozzi forceps came to the fore. This cervical tenaculum—a sharp, clamp-like tool traditionally used to stabilise the cervix during gynaecological procedures, is often a source of pain, bleeding and stress for patients.
From this discussion, with the help of Mathieu Horras, co-founder and medical device expert, Carevix™ was born, a modern alternative that stabilises the cervix with gentle suction, eliminating the adverse effects associated with traditional forceps. Simple yet powerful, the product is protected by several patents.
Carevix™ is currently FDA-Cleared for the US market, CE-Marked for the EU market, and authorized in the UK and Brazil. It is available for commercialization, and is already available in a network of clinics in the US.
Aspivix: Born In The Swiss Health Valley
Based in the canton of Vaud, Aspivix has benefited from a unique ecosystem, including partnerships with CHUV, EPFL and HEIG-VD, as well as support from initiatives such as Innosuisse and Innovaud. This combination of talent and resources has enabled the start-up to conduct a successful clinical study with CHUV, while attracting strategic collaborations, notably with Bayer in 2024.
Carevix™ was also listed among the 200 best inventions of 2024 by Time magazine, a recognition that reinforces its legitimacy and global growth potential.
Source : Capital Cell